Psychedelic Drugs Market

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. History of Psychedelic Substances
3.3. Potential Therapeutic Applications of Psychedelic Substances
3.4. Regulation, Toxicity Concerns, Procurement-related Challenges and Perceptions Regarding Medical Use
3.5. Future Opportunities

4. MARKET LANDSCAPE: PSYCHEDELIC THERAPEUTICS
4.1. Chapter Overview
4.2. Psychedelic Therapeutics: Marketed and Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Psychedelic Substance
4.2.3. Analysis by Origin of Psychedelic Substance
4.2.4. Analysis by Target Therapeutic Area
4.2.5. Analysis by Route of Administration
4.2.6. Analysis by Dosing Frequency

4.3. Psychedelic Therapeutics: List of Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size

4. 3.3. Analysis by Location of Headquarters
4.4. Grid Analysis: Distribution by Phase of Development, Origin of Psychedelic Substance and Location of Headquarters

5. COMPANY PROFILES
5.1. Chapter Overview

5.2. Celon Pharma
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Psychedelic Therapeutics Portfolio
5.2.3.1. Esketamine DPI
5.2.4. Recent Developments and Future Outlook

5.3. iX Biopharma
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Psychedelic Therapeutics Portfolio
5.3.3.1. Wafermine™
5.3.3.2. Unnamed (Ketamine)
5.3.4. Recent Developments and Future Outlook

5.4. MAPS Public Benefit
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Psychedelic Therapeutics Portfolio
5.4.3.1. Unnamed (MDMA)
5.4.3.2. Unnamed (Ibogaine Hydrochloride)
5.4.3.3. Unnamed (LSD)
5.4.3.4. Unnamed (Ayahuasca)
5.4.4. Recent Developments and Future Outlook

5.5. MindMed
5.5.1. Company Overview
5.5.2. Psychedelic Therapeutics Portfolio
5.5.2.1. LSD Micro-dosing
5.5.2.2. 18-MC
5.5.2.3. Unnamed (LSD and MDMA)
5.5.3. Recent Developments and Future Outlook

5.6. Janssen Pharmaceuticals
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Psychedelic Therapeutics Portfolio
5.6.3.1. SPRAVATO®
5.6.4. Recent Developments and Future Outlook

5.7. Jazz Pharmaceutical
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Psychedelic Therapeutics Portfolio
5.7.3.1. XYREM®
5.7.3.2. JZP-258
5.7.3.3. JZP-324
5.7.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Psychedelic Therapeutics: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Phase
6.3.3. Analysis by Trial Recruitment Status
6.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
6.3.5. Analysis by Study Design
6.3.6. Leading Trial Sponsors: Analysis by Number of Registered Trials
6.3.7. Leading Industry Sponsors: Analysis by Number of Registered Trials
6.3.8. Word Cloud: Key Focus Areas
6.3.9. Analysis by Target Therapeutic Area
6.3.10. Popular Interventions: Analysis by Number of Registered Trials
6.3.11. Geographical Analysis by Number of Registered Trials
6.3.12. Geographical Analysis by Trial Recruitment Status
6.3.13. Geographical Analysis by Number of Patients Enrolled

7. CLINICAL TRIAL SITE ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Psychedelic Therapeutics: Clinical Trial Site Analysis
7.3.1. Analysis by Type of Psychedelic Substance
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Target Therapeutic Area
7.3.4. Analysis by Location of Clinical Trial Site

8. KEY OPINION LEADER (KOL) ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Methodology
8.3. Principal Investigators Involved in Clinical Trials
8.3.1. Analysis by Type of Organization (KOL Affiliation)
8.3.2. Geographical Distribution of KOLs

8.4. Prominent KOLs
8.5. KOL Benchmarking: Roots Analysis’ Assessment versus Third Party (ResearchGate Score)
8.6. Most Active KOLs
8.6.1. KOL Profile: A (Emory School of Medicine)
8.6.2. KOL Profile: B (Imperial College London)
8.6.3. KOL Profile: C (Rigshospitalet)
8.6.4. KOL Profile: D (Thriving Mind South Florida)
8.6.5. KOL Profile: E (University Health Network)

9. ACADEMIC GRANTS ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Psychedelic Therapeutics: Analysis of Academic Grants
9.3.1. Analysis by Year of Grant Award
9.3.2. Analysis by Amount Awarded
9.3.3. Analysis by Funding Institute Center
9.3.4. Analysis by Support Period
9.3.5. Analysis by Funding Institute Center and Support Period
9.3.6. Analysis by Type of Grant Application
9.3.7. Analysis by Purpose of Grant Award
9.3.8. Analysis by Activity Code
9.3.9. Analysis by Study Section Involved
9.3.10. Analysis by Recipient Organization
9.3.11. Geographical Distribution of Recipient Organizations
9.3.12. Word Cloud: Emerging Focus Areas
9.3.13. Popular Psychedelic Therapeutics: Analysis by Number of Grants
9.3.14. Popular Funding Institute Centers: Analysis by Number of Grants
9.3.15. Prominent Program Officers: Analysis by Number of Grants
9.3.16. Popular Recipient Organizations: Analysis by Number of Grants

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Psychedelic Therapeutics: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Type of Partnership and Type of Psychedelic Substance Involved
10.3.4. Analysis by Type of Partnership and Phase of Development of Involved Intervention
10.3.5. Analysis by Type of Partnership and Target Therapeutic Area Mentioned
10.3.6. Analysis by Type of Psychedelic Substance and Target Therapeutic Area
10.3.7. Analysis by Type of Partnership and Type of Partner
10.3.8. Analysis by Type of Psychedelic Substance Involved and Type of Partner
10.3.9. Most Active Players: Analysis by Number of Partnerships
10.3.10. Regional Analysis
10.3.10.1 Intercontinental and Intracontinental Agreements

11. MERGERS AND ACQUISITIONS
11.1. Chapter Overview
11.2. Acquisition Models
11.3. Psychedelic Therapeutics: Mergers and Acquisitions
11.3.1. Cumulative Year-wise Trend of Mergers and Acquisitions
11.3.2. Analysis by Type of Acquisition
11.3.3. Analysis by Type of Psychedelic Substance Involved
11.3.4. Analysis by Year of Acquisition and Type of Psychedelic Substance Involved
11.3.5. Most Active Players: Analysis by Number of Acquisitions
11.3.6. Regional Analysis
11.3.6.1. Continent-Wise Distribution of Acquisitions
11.3.6.2. Country-Wise Distribution of Acquisitions
11.3.7. Analysis by Key Value Drivers
11.3.7.1, Analysis by Year of Acquisition and Key Value Drivers

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Assumptions
12.3. Global Psychedelic Therapeutics Market, 2020-2030
12.4. Global Psychedelic Therapeutics Market: Individual Product Sales Forecasts

12.4.1. COMP360 (COMPASS Pathways)
12.4.1.1. Target Patient Population
12.4.1.2. Sales Forecast

12.4.2. Esketamine DPI (Celon Pharma)
12.4.2.1. Target Patient Population
12.4.2.2. Sales Forecast

12.4.3. FT218 (Avadel Pharmaceuticals)
12.4.3.1. Target Patient Population
12.4.3.2. Sales Forecast

12.4.4. JZP-258 (Jazz Pharmaceuticals)
12.4.4.1. Target Patient Population
12.4.4.2. Sales Forecast

12.4.5. NRX-100 (NeuroRx)
12.4.5.1. Target Patient Population
12.4.5.2. Sales Forecast

12.4.6. R-107 (Doughlas pharmaceuticals)
12.4.6.1. Target Patient Population
12.4.6.2. Sales Forecast

12.4.7. SPRAVATO® (Janssen Pharmaceuticals)
12.4.7.1. Target Patient Population
12.4.7.2. Sales Forecast

12.4.8. Unnamed (MDMA) (MAPS Public Benefit)
12.4.8.1. Target Patient Population
12.4.8.2. Sales Forecast

12.4.9. Unnamed (Psilocybin) (The Emmes Company)
12.4.9.1. Target Patient Population
12.4.9.2. Sales Forecast

12.4.10. Wafermine™ (iX Biopharma)
12.4.10.1. Target Patient Population
12.4.10.2. Sales Forecast

12.4.11. XYREM® (Jazz Pharmaceuticals)
12.4.11.1. Target Patient Population
12.4.11.2. Sales Forecast

12.5. Global Psychedelic Therapeutics Market: Distribution by Origin of Psychedelic Substance, 2020-2030
12.5.1. Global Psychedelic Therapeutics Market for Synthetic Substances, 2020-2030
12.5.2. Global Psychedelic Therapeutics Market for Natural Substances, 2020-2030

12.6. Global Psychedelic Therapeutics Market: Distribution by Type of Psychedelic Substance, 2020-2030
12.6.1. Global Psychedelic Therapeutics Market for GHB, 2020-2030
12.6.2. Global Psychedelic Therapeutics Market for Ketamine, 2020-2030
12.6.3. Global Psychedelic Therapeutics Market for MDMA, 2020-2030
12.6.4. Global Psychedelic Therapeutics Market for Psilocybin, 2020-2030

12.7. Global Psychedelic Therapeutics Market: Distribution by Geography, 2020-2030
12.7.1. Psychedelic Therapeutics Market in North America, 2020-2030
12.7.2. Psychedelic Therapeutics Market in Europe, 2020-2030
12.7.3. Psychedelic Therapeutics Market in Asia-Pacific and Rest of the World, 2020-2030

12.8. Psychedelic Therapeutics Market: Distribution by Target Therapeutic Area, 2020-2030
12.8.1. Global Psychedelic Therapeutics Market for Depression and Anxiety Disorders, 2020-2030
12.8.2. Global Psychedelic Therapeutics Market for Pain Disorders, 2020-2030
12.8.3. Global Psychedelic Therapeutics Market for Sleep-Related Disorders, 2020-2030
12.8.4. Global Psychedelic Therapeutics Market for Trauma, 2020-2030

12.9. Global Psychedelic Therapeutics Market: Distribution by Route of Administration, 2020-2030
12.9.1. Global Psychedelic Therapeutics Market for Intranasal Therapies, 2020-2030
12.9.2. Global Psychedelic Therapeutics Market for Intravenous Therapies, 2020-2030
12.9.3. Global Psychedelic Therapeutics Market for Oral Therapies, 2020-2030
12.9.4. Global Psychedelic Therapeutics Market for Sublingual Therapies, 2020-2030

13. CONCLUDING REMARKS
13.1. Chapter Overview
13.2. Key Takeaways

14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2 CaaMTech
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Andrew Chadeayne, Founder & Chief Executive Officer

14.3. MindMed
14.3.1. Company Snapshot
14.3.2. Interview Transcript: JR Rahn, Founder & Chief Executive Officer

14.4. iX Biopharma
14.4.1. Company Snapshot
14.4.2. Interview Transcript: Janakan Krishnarajah, Chief Operating Officer and Chief Medical Officer

14.5 Orthogonal Thinkers
14.5.1. Company Snapshot
14.5.2. Interview Transcript: Tracy Cheung, Alexander Speiser, Chief Operating Officer

14.6 COMPASS Pathways
14.6.1. Company Snapshot
14.6.2. Interview Transcript: Tracy Cheung, Chief Communications Officer
14.7 Yale University
14.7.1. Company Snapshot
14.7.2. Interview Transcript: Benjamin Kelmendi, Assistant Professor of Psychiatry

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1. Historical Evolution of Psychedelics
Figure 3.2. Psychedelic Substances: Potential Therapeutic Areas
Figure 3.3. Classification of Psychedelic Substances under the Federal Controlled Substances Act
Figure 3.4. Psychedelic Therapeutics: Status of Legalization / Decriminalization Across Different Geographies
Figure 3.5. Psychedelic Therapeutics: Toxicity Comparison of Different Substances
Figure 4.1. Psychedelic Therapeutics: Distribution by Phase of Development
Figure 4.2. Psychedelic Therapeutics: Distribution by Type of Psychedelic Substance
Figure 4.3. Psychedelic Therapeutics: Distribution by Origin of Psychedelic Substance
Figure 4.4. Psychedelic Therapeutics: Distribution by Target Therapeutic Area
Figure 4.5. Psychedelic Therapeutics: Distribution by Route of Administration
Figure 4.6. Psychedelic Therapeutics: Distribution by Dosing Frequency
Figure 4.7. Psychedelic Therapeutics Developers: Distribution by Year of Establishment
Figure 4.8. Psychedelic Therapeutics Developers: Distribution by Company Size
Figure 4.9. Psychedelic Therapeutics Developers: Distribution by Location of Headquarters
Figure 4.10. Grid Representation: Distribution by Phase of Development, Origin of Psychedelic Substance and Location of Headquarters
Figure 5.1. Celon Pharma: Annual Revenues, 2016- 2019 (PLN Million)
Figure 5.2. iX Biopharma: Annual Revenues, 2015- 2019 (USD Million)
Figure 5.3. MAPS Public Benefit: Annual Revenues, 2016- Q1 2020 (USD Million)
Figure 5.4. Janssen Pharmaceuticals: Annual Revenues, 2016- Q1 2020 (USD Million)
Figure 5.5. Jazz Pharmaceutical: Annual Revenues, 2015- Q1 2020 (USD Million)
Figure 6.1. Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year
Figure 6.2. Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.3. Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 6.4. Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled
Figure 6.5. Clinical Trial Analysis: Distribution by Study Design
Figure 6.6. Leading Trial Sponsors: Distribution by Number of Registered Trials
Figure 6.7. Leading Industry Sponsors: Distribution by Number of Registered Trials
Figure 6.8. Word Cloud: Key Focus Areas
Figure 6.9. Clinical Trial Analysis: Distribution by Target Therapeutic Area
Figure 6.10. Popular Interventions: Distribution by Number of Registered Trials
Figure 6.11. Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 6.12. Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
Figure 6.13. Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Figure 7.1. Clinical Trial Site Analysis: Cumulative Distribution of Clinical Trial Centre
Figure 7.2. Clinical Trial Site Analysis: Distribution by Type of Psychedelic Substance
Figure 7.3. Clinical Trial Site Analysis: Distribution by Trial Phase
Figure 7.4. Clinical Trial Site Analysis: Distribution by Target Therapeutic Area
Figure 7.5. Clinical Trial Site Analysis: Distribution by Location of Clinical Trial Center
Figure 8.1. KOL Analysis: Distribution by Type of Organization (KOL Affiliation)
Figure 8.2. KOL Analysis: Geographical Distribution of KOLs in America
Figure 8.3. KOL Analysis: Geographical Distribution of KOLs in Europe, Asia-Pacific and RoW
Figure 8.4. KOL Analysis: Distribution by Location of Organization (KOL Affiliation)
Figure 8.5. KOL Analysis: Leading Organizations (KOL Affiliation)
Figure 8.6. KOL Analysis: Dot-Plot of KOLs
Figure 8.7. KOL Benchmarking: Roots Analysis’ Assessment versus Third Party (ResearchGate Score)
Figure 8.8. KOL Analysis: Most Prominent KOLs
Figure 9.1. Grant Analysis: Cumulative Trend by Year of Grant Award, 2015-2020
Figure 9.2. Grant Analysis: Cumulative Distribution by Amount Awarded, 2015-2020 (USD Million)
Figure 9.3. Grant Analysis: Distribution by Funding Institute Center
Figure 9.4. Grant Analysis: Distribution by Support Period
Figure 9.5. Grant Analysis: Distribution by Funding Institute Center and Support Period
Figure 9.6. Grant Analysis: Distribution by Type of Grant Application
Figure 9.7. Grant Analysis: Distribution by Purpose of Grant Award
Figure 9.8. Grant Analysis: Distribution by Activity Code
Figure 9.9. Grant Analysis: Distribution by Study Section Involved
Figure 9.10. Grant Analysis: Distribution by Recipient Organization
Figure 9.11. Grant Analysis: Regional Distribution of Recipient Organizations
Figure 9.12. Word Cloud Analysis: Emerging Focus Areas
Figure 9.13. Popular Psychedelic Therapeutics: Distribution by Number of Grants
Figure 9.14. Popular Funding Institute Centers: Distribution by Number of Grants
Figure 9.15. Grant Analysis: Prominent Program Officers
Figure 9.16. Popular Recipient Organizations: Distribution by Number of Grants
Figure 10.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2020
Figure 10.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Psychedelic Substance Involved
Figure 10.4. Partnerships and Collaborations: Distribution by Type of Partnership and Phase of Development of Involved Intervention
Figure 10.5. Partnerships and Collaborations: Distribution by Type of Psychedelic Substance and Target Therapeutic Area
Figure 10.6. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 10.7. Partnerships and Collaborations: Distribution by Type of Psychedelic Substance Involved and Type of Partner
Figure 10.8. Most Active Players: Distribution by Number of Partnerships
Figure 10.9. Partnership and Collaborations: Regional Distribution
Figure 10.10. Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 11.1. Mergers and Acquisitions: Cumulative Year-wise Trend, 2017-2020
Figure 11.2. Mergers and Acquisitions: Distribution by Type of Acquisition
Figure 11.3. Mergers and Acquisitions: Distribution by Type of Psychedelic Substance Involved
Figure 11.4. Mergers and Acquisitions: Distribution by Year of Acquisition and Type of Psychedelic Substance Involved
Figure 11.5. Most Active Players: Distribution by Number of Acquisition
Figure 11.6. Mergers and Acquisitions: Regional Distribution
Figure 11.7. Mergers and Acquisitions: Intercontinental and Intracontinental Deals
Figure 11.8. Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 11.9. Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 12.1. Global Psychedelic Therapeutics Market, 2020-2030 (USD Million)
Figure 12.2. COMP360 (COMPASS Pathways): Target Patient Population
Figure 12.3. COMP360 (COMPASS Pathways): Sales Forecast
Figure 12.4. Esketamine DPI (Celon Pharma): Target Patient Population
Figure 12.5. Esketamine DPI (Celon Pharma): Sales Forecast
Figure 12.6. FT218 (Avadel Pharmaceuticals): Target Patient Population
Figure 12.7. FT218 (Avadel Pharmaceuticals): Sales Forecast
Figure 12.8. JZP-258 (Jazz Pharmaceuticals): Target Patient Population
Figure 12.9. JZP-258 (Jazz Pharmaceuticals): Sales Forecast
Figure 12.10. NRX-100 (NeuroRx): Target Patient Population
Figure 12.11. NRX-100 (NeuroRx): Sales Forecast
Figure 12.12. R-107 (Doughlas pharmaceuticals): Target Patient Population
Figure 12.13. R-107 (Doughlas pharmaceuticals): Sales Forecast
Figure 12.14. SPRAVATO® (Janssen Pharmaceuticals): Target Patient Population
Figure 12.15. SPRAVATO® (Janssen Pharmaceuticals): Sales Forecast
Figure 12.16. Unnamed (MDMA) (MAPS Public Benefit): Target Patient Population
Figure 12.17. Unnamed (MDMA) (MAPS Public Benefit): Sales Forecast
Figure 12.18. Unnamed (Psilocybin) (The Emmes Company): Target Patient Population
Figure 12.19. Unnamed (Psilocybin) (The Emmes Company): Sales Forecast
Figure 12.20. Wafermine™ (iX Biopharma): Target Patient Population
Figure 12.21. Wafermine™ (iX Biopharma): Sales Forecast
Figure 12.22. XYREM® (Jazz Pharmaceuticals): Target Patient Population
Figure 12.23. XYREM® (Jazz Pharmaceuticals): Sales Forecast
Figure 12.24. Global Psychedelic Therapeutics Market: Distribution by Origin of Psychedelic Substances, 2020-2030 (USD Million)
Figure 12.25. Global Psychedelic Therapeutics Market for Synthetic Substances, 2020-2030
Figure 12.26. Global Psychedelic Therapeutics Market for Natural Substances, 2020-2030
Figure 12.27. Global Psychedelic Therapeutics Market: Distribution by Type of Psychedelic Substance, 2020-2030 (USD Million)
Figure 12.28. Global Psychedelic Therapeutics Market for GHB, 2020-2030
Figure 12.29. Global Psychedelic Therapeutics Market for Ketamine, 2020-2030
Figure 12.30. Global Psychedelic Therapeutics Market for MDMA, 2020-2030
Figure 12.31. Global Psychedelic Therapeutics Market for Psilocybin, 2020-2030
Figure 12.32. Global Psychedelic Therapeutics Market: Distribution by Geography, 2020-2030 (USD Million)
Figure 12.33. Global Psychedelic Therapeutics Market in North America, 2020-2030 (USD Million)
Figure 12.34. Global Psychedelic Therapeutics Market in Europe, 2020-2030 (USD Million)
Figure 12.35. Global Psychedelic Therapeutics Market in Asia Pacific and Rest of the World, 2020-2030 (USD Million)
Figure 12.36. Psychedelic Therapeutics Market: Distribution by Target Therapeutic Area, 2020-2030 (USD Million)
Figure 12.37. Global Psychedelic Therapeutics Market for Depression and Anxiety Disorders, 2020-2030 (USD Million)
Figure 12.38. Global Psychedelic Therapeutics Market for Pain Disorders, 2020-2030 (USD Million)
Figure 12.39. Global Psychedelic Therapeutics Market for Sleep-Related Disorders, 2020-2030 (USD Million)
Figure 12.40. Global Psychedelic Therapeutics Market for Trauma, 2020-2030 (USD Million)
Figure 12.41. Global Psychedelic Therapeutics Market: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 12.42. Global Psychedelic Therapeutics Market for Intranasal Therapies, 2020-2030 (USD Million)
Figure 12.43. Global Psychedelic Therapeutics Market for Intravenous Therapies, 2020-2030 (USD Million)
Figure 12.44. Global Psychedelic Therapeutics Market for Oral Therapies, 2020-2030 (USD Million)
Figure 12.45. Global Psychedelic Therapeutics Market for Sublingual Therapies, 2020-2030 (USD Million)

List of Tables

Table 4.1. Psychedelic Therapeutics: Marketed and Development Pipeline
Table 4.2. Psychedelic Therapeutics: List of Developers
Table 5.1. Psychedelic Therapeutics: List of Companies Profiled
Table 5.2. Celon Pharma: Company Snapshot 
Table 5.3. Drug Profile: Esketamine DPI
Table 5.4. Celon Pharma: Recent Developments and Future Outlook
Table 5.5. iX Biopharma: Company Snapshot
Table 5.6. Drug Profile: Wafermine®
Table 5.7. Drug Profile: Unnamed (Ketamine)
Table 5.8. iX Biopharm: Recent Developments and Future Outlook
Table 5.9. MAPS Public Benefit: Company Snapshot
Table 5.10. Drug Profile: Unnamed (MDMA)
Table 5.11. Drug Profile: Unnamed Ibogaine Hydrochloride
Table 5.12. Drug Profile: Unnamed (LSD)
Table 5.13. Drug Profile: Unnamed (Ayahuasca)
Table 5.14. MAPS Public Benefit: Recent Developments and Future Outlook
Table 5.15. MindMed: Company Snapshot
Table 5.16. Drug Profile: LSD Micro-Dosing
Table 5.17. Drug Profile: 18-MC
Table 5.18. MindMed: Recent Developments and Future Outlook
Table 5.19. Janssen Pharmaceutical: Company Snapshot
Table 5.20. Drug Profile: SPRAVATO®
Table 5.21. Janssen Pharmaceutical: Recent Developments and Future Outlook
Table 5.22. Jazz Pharmaceutical: Company Snapshot
Table 5.23. Drug Profile: XYREM®
Table 5.24. Drug Profile: JZP-258
Table 5.25. Drug Profile: JZP-324
Table 5.26. Jazz pharmaceutical: Recent Developments and Future Outlook
Table 7.1. Psychedelic Therapeutics: List of Principal Investigators
Table 7.2. KOLs: Roots Analysis Proprietary Scoring System
Table 7.3. KOL Profile:  A (Emory School of Medicine)
Table 7.4. KOL Profile: B (Imperial College London)
Table 7.5. KOL Profile: C (Rigshospitalet)
Table 7.6. KOL Profile: D (Thriving Mind South Florida)
Table 7.7. KOL Profile: E (University Health Network)
Table 10.1. Psychedelic Therapeutics: List of Partnerships and Collaborations
Table 11.1. Psychedelic Therapeutics: List of Mergers and Acquisition
Table 11.2. Psychedelic Therapeutics: Key Growth Drivers
Table.15.1. Psychedelic Therapeutics: Distribution by Phase of Development
Table.15.2. Psychedelic Therapeutics: Distribution by Type of Psychedelic Substance
Table.15.3. Psychedelic Therapeutics: Distribution by Origin of Psychedelic Substance
Table.15.4. Psychedelic Therapeutics: Distribution by Target Therapeutic Area
Table.15.5. Psychedelic Therapeutics: Distribution by Route of Administration
Table.15.6. Psychedelic Therapeutics: Distribution by Dosing Frequency
Table.15.7. Psychedelic Therapeutics Developers: Distribution by Year of Establishment
Table.15.8. Psychedelic Therapeutics Developers: Distribution by Company Size
Table.15.9. Celon Pharma: Annual Revenues, 2016- 2019 (PLN Million)
Table.15.10. iX Biopharma: Annual Revenues, 2015- 2019 (USD Million)
Table.15.11. MAPS Public Benefit: Annual Revenues, 2016- Q1 2020 (USD Million)
Table.15.12. Janssen Pharmaceuticals: Annual Revenues, 2016- Q1 2020 (USD Million)
Table.15.13. Jazz Pharmaceutical: Annual Revenues, 2015- Q1 2020 (USD Million)
Table.15.14. Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year
Table.15.15. Clinical Trial Analysis: Distribution by Trial Phase
Table.15.16. Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table.15.17. Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled
Table.15.18. Clinical Trial Analysis: Distribution by Study Design
Table.15.19. Leading Trial Sponsors: Distribution by Number of Registered Trials
Table.15.20. Leading Industry Sponsors: Distribution by Number of Registered Trials
Table.15.21. Clinical Trial Analysis: Distribution by Target Therapeutic Area
Table.15.22. Popular Interventions: Distribution by Number of Registered Trials
Table.15.23. Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Table.15.24. Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
Table.15.25. Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Table.15.26. Clinical Trial Site Analysis: Cumulative Distribution of Clinical Trial Centre
Table.15.27. Clinical Trial Site Analysis: Distribution by Type of Psychedelic Substance
Table.15.28. Clinical Trial Site Analysis: Distribution by Trial Phase
Table.15.29. Clinical Trial Site Analysis: Distribution by Target Therapeutic Area
Table.15.30. Clinical Trial Site Analysis: Distribution by Location of Clinical Trial Center
Table.15.31. KOL Analysis: Distribution by Type of Organization (KOL Affiliation)
Table.15.32. KOL Analysis: Distribution by Location of Organization (KOL Affiliation)
Table.15.33. KOL Analysis: Leading Organizations (KOL Affiliation)
Table.15.34. KOL Benchmarking: Roots Analysis’ Assessment versus Third Party (ResearchGate Score)
Table.15.35. KOL Analysis: Most Prominent KOLs
Table.15.36. Grant Analysis: Cumulative Trend by Year of Grant Award, 2015-2020
Table.15.37. Grant Analysis: Cumulative Distribution by Amount Awarded, 2015-2020 (USD Million)
Table.15.38. Grant Analysis: Distribution by Funding Institute Center
Table.15.39. Grant Analysis: Distribution by Support Period
Table.15.40. Grant Analysis: Distribution by Funding Institute Center and Support Period
Table.15.41. Grant Analysis: Distribution by Type of Grant Application
Table.15.42. Grant Analysis: Distribution by Purpose of Grant Award
Table.15.43. Grant Analysis: Distribution by Activity Code
Table.15.44. Grant Analysis: Distribution by Study Section Involved
Table.15.45. Grant Analysis: Distribution by Recipient Organization
Table.15.46. Word Cloud Analysis: Emerging Focus Areas
Table.15.47. Popular Psychedelic Therapeutics: Distribution by Number of Grants
Table.15.48. Popular Funding Institute Centers: Distribution by Number of Grants
Table.15.49. Grant Analysis: Prominent Program Officers
Table.15.50. Popular Recipient Organizations: Distribution by Number of Grants
Table.15.51. Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2020
Table.15.52. Partnerships and Collaborations: Distribution by Type of Partnership
Table.15.53. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Psychedelic Substance Involved
Table.15.54. Partnerships and Collaborations: Distribution by Type of Partnership and Phase of Development of Involved Intervention
Table.15.55. Partnerships and Collaborations: Distribution by Type of Psychedelic Substance and Target Therapeutic Area
Table.15.56. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table.15.57. Partnerships and Collaborations: Distribution by Type of Psychedelic Substance Involved and Type of Partner
Table.15.58. Most Active Players: Distribution by Number of Partnerships
Table.15.59. Partnership and Collaborations: Regional Distribution
Table.15.60. Mergers and Acquisitions: Cumulative Year-wise Trend, 2017-2020
Table.15.61. Mergers and Acquisitions: Distribution by Type of Acquisition
Table.15.62. Mergers and Acquisitions: Distribution by Type of Psychedelic Substance Involved
Table.15.63. Mergers and Acquisitions: Distribution by Year of Acquisition and Type of Psychedelic Substance Involved
Table.15.64. Most Active Players: Distribution by Number of Acquisition
Table.15.65. Mergers and Acquisitions: Regional Distribution
Table.15.66. Mergers and Acquisitions: Distribution by Key Value Drivers
Table.15.67. Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Table.15.68. Global Psychedelic Therapeutics Market, 2020-2030 (USD Million)
Table.15.69. COMP360 (COMPASS Pathways): Sales Forecast
Table.15.70. Esketamine DPI (Celon Pharma): Sales Forecast
Table.15.71. FT218 (Avadel Pharmaceuticals): Sales Forecast
Table.15.72. JZP-258 (Jazz Pharmaceuticals): Sales Forecast
Table.15.73. NRX-100 (NeuroRx): Sales Forecast
Table.15.74. R-107 (Doughlas pharmaceuticals): Sales Forecast
Table.15.75. SPRAVATO® (Janssen Pharmaceuticals): Sales Forecast
Table.15.76. Unnamed (MDMA) (MAPS Public Benefit): Sales Forecast
Table.15.77. Unnamed (Psilocybin) (The Emmes Company): Sales Forecast
Table.15.78. Wafermine™ (iX Biopharma): Sales Forecast
Table.15.79. XYREM® (Jazz Pharmaceuticals): Sales Forecast
Table.15.80. Global Psychedelic Therapeutics Market: Distribution by Origin of Psychedelic Substances, 2020-2030 (USD Million)
Table.15.81. Global Psychedelic Therapeutics Market for Synthetic Substances, 2020-2030 (USD Million)
Table.15.82. Global Psychedelic Therapeutics Market for Natural Substances, 2020-2030 (USD Million)
Table.15.83. Global Psychedelic Therapeutics Market: Distribution by Type of Psychedelic Substance, 2020-2030 (USD Million)
Table.15.84. Global Psychedelic Therapeutics Market for GHB, 2020-2030 (USD Million)
Table.15.85. Global Psychedelic Therapeutics Market for Ketamine, 2020-2030 (USD Million)
Table.15.86. Global Psychedelic Therapeutics Market for MDMA, 2020-2030 (USD Million)
Table.15.87. Global Psychedelic Therapeutics Market for Psilocybin, 2020-2030 (USD Million)
Table.15.88. Global Psychedelic Therapeutics Market: Distribution by Geography, 2020-2030 (USD Million)
Table.15.89. Global Psychedelic Therapeutics Market in North America, 2020-2030 (USD Million)
Table.15.90. Global Psychedelic Therapeutics Market in Europe, 2020-2030 (USD Million)
Table.15.91. Global Psychedelic Therapeutics Market in Asia Pacific and Rest of the World, 2020-2030 (USD Million)
Table.15.92. Psychedelic Therapeutics Market: Distribution by Target Therapeutic Area, 2020-2030 (USD Million)
Table.15.93. Global Psychedelic Therapeutics Market for Depression and Anxiety Disorders, 2020-2030 (USD Million)
Table.15.94. Global Psychedelic Therapeutics Market for Pain Disorders, 2020-2030 (USD Million)
Table.15.95. Global Psychedelic Therapeutics Market for Sleep-Related Disorders, 2020-2030 (USD Million)
Table.15.96. Global Psychedelic Therapeutics Market for Trauma, 2020-2030 (USD Million)
Table.15.97. Global Psychedelic Therapeutics Market: Distribution by Route of Administration, 2020-2030 (USD Million)
Table.15.98. Global Psychedelic Therapeutics Market for Intranasal Therapies, 2020-2030 (USD Million)

Listed Companies

1. Absolem Health
2. Acres Agricultural Canada
3. Ajou University
4. Allevio Pain Management Clinic
5. Alphamind Brands
6. Alternating Hemiplegia of Childhood Foundation
7. AltMed Capital
8. Ambroise-Paré Hospital
9. Apricus Biosciences
10. Artisan Growers
11. Assiut University
12. ATAI Life Sciences
13. Avadel Pharmaceuticals
14. Baylor College of Medicine
15. Beijing Tiantan Hospital
16. Beth Israel Deaconess Medical Center
17. Brown University
18. BurstIQ
19. CaaMTech
20. Cairo University
21. Carilion Clinic
22. Cedars-Sinai
23. Celon Pharma
24. Center Hospitalier de Cayenne Andrée Rosemon
25. Centre Hospitalier de Valenciennes
26. Champignon Brands
27. Children’s Hospital & Medical Center
28. China Academy of Chinese Medical Sciences
29. Cleveland Clinic
30. Columbia University
31. COMPASS Pathways
32. Complete Phytochemical Solutions
33. Cooper University Health Care
34. Copenhagen University Hospital
35. Cukurova University
36. Cybin
37. Cyclica
38. DemeRx
39. Develco Pharma Schweiz
40. Dosed Wellness
41. Douglas Pharmaceuticals
42. Ehave
43. Eleusis Benefit
44. Emory University
45. Entheogenix Biosciences
46. Entheon Biomedical
47. Erciyes University
48. Erzincan Binali Yildirim University
49. Federal University of Santa Catarina
50. Field Trip Health
51. Flamel Technologies
52. Frontier Neurochem
53. Germans Trias i Pujol Research Institute
54. Ghent University Hospital
55. Gilgamesh Pharmaceuticals
56. Grenoble Alpes University Hospital
57. Guangzhou Women and Children's Medical Center
58. Gui de Chauliac Hospital
59. Harvard Medical School
60. Harvard University
61. Hollister Biosciences
62. Hospital de Clínicas de Porto Alegre
63. Hospital Universitari Sant Joan de Reus
64. Icahn School of Medicine
65. Imperial College London
66. Infan Industria Quimica Farmaceutica Nacional
67. Inönü University
68. Institute of Basic Research in Clinical Medicine
69. Instituto Mexicano del Seguro Social
70. International Center for Ethnobotanical Education, Research, and Service
71. iX Biopharma
72. James J. Peters Veterans Affairs Medical Center 
73. Janssen Pharmaceuticals
74. Jazz Pharmaceuticals
75. JBR Clinical Research
76. Johns Hopkins University
77. Kingdom Brands
78. KK Women's and Children's Hospital
79. Klarisana
80. Klinik Barmelweid
81. Lindner Center of HOPE
82. Lotus Clinical Research
83. Lund University
84. Maastricht University
85. Maimonides Medical Center
86. Makerere University
87. Massachusetts General Hospital
88. Mayo Clinic
89. Mayo Foundation for Medical Education and Research
90. McGill University
91. Medical College of Wisconsin
92. Medical University of Gdansk
93. Medical University of South Carolina
94. Medical University of Vienna
95. Medrio
96. MercyOne Des Moines Medical Center
97. Miami University
98. MindMed
99. Mind Mental Health Technologies
100. Mindset Pharma
101. Minneapolis Veterans Affairs Health Care System 
102. MJ MedTech
103. Montpellier University Hospital
104. Multidisciplinary Association for Psychedelic Studies
105. Mycology Ventures
106. Mycotopia Therapy (subsidiary of Ehave)
107. Mydecine Group (subsidiary of NewLeaf Brands)
108. MyLifeID
109. Nanjing University
110. Nathan S. Kline Institute for Psychiatric Research
111. National Center for Research and Development
112. National Hospital for Neurology and Neurosurgery
113. National Institute of Mental Health
114. National Institute of Nursing Research
115. National Institute on Drug Abuse
116. Nationwide Children's Hospital
117. NeonMind Biosciences
118. Neurocentrx Pharma
119. NeuroRx
120. New Hanover Regional Medical Center
121. NewLeaf Brands
122. Northwestern University
123. Novo Formulations
124. Numinus Wellness
125. New York University Grossman School of Medicine
126. NYU Langone Health
127. Octarine Bio
128. Ohio State University Wexner Medical Center 
129. Orphan Medical
130. Orthogonal Thinker
131. Päijät-Häme Welfare Association
132. Parc de Salut Mar
133. Peking University First Hospital
134. Penn State Health Milton S. Hershey Medical Center
135. Perception Neuroscience (subsidiary of ATAI Life Sciences)
136. Pharmaron
137. Pontifical Catholic University of São Paulo
138. Princess Margaret Cancer Centre
139. Providence Care Hospital
140. Psilocin Pharma (subsidiary of Revive Therapeutics)
141. PsyBio Therapeutics
142. PsychedeliTech (subsidiay of Ehave)
143. Psygen
144. Psytech
145. PureTech Health
146. Radboud University
147. Regions Hospital
148. Revive Therapeutics
149. Rutgers, The State University of New Jersey
150. Saint Louis University
151. Sansero Life Sciences
152. Seelos Therapeutics
153. Seoul National University Hospital
154. Sévigné Private Hospital
155. Shalvata Mental Health Center
156. Shenox Pharmaceuticals
157. Signant Health
158. Small Pharma
159. Spital Limmattal
160. St. Justine's Hospital
161. St. Luke's Hospital
162. St. Michael's Hospital
163. St. Patrick’s University Hospital
164. Stanford University
165. Swiss Medical Society for Psycholytic Therapy
166. Syntac Therapeutics
167. Taipei City Hospital
168. Target Health
169. Tassili Life Sciences
170. The Brooklyn Hospital Center
171. The Cleveland Clinic
172. The Emmes Company
173. The Lundquist Institute
174. The Neuroscience Center
175. The University of Alabama at Birmingham
176. The University of Hong Kong
177. The University of Texas Health Science Center at Houston 
178. The Vanguard Group
179. The Wellness Clinic
180. TheraPsil
181. Toronto Centre for Psychedelic Science
182. Translational Life Sciences
183. UCB Pharma
184. Universal Ibogaine
185. Universidad Autónoma de Madrid
186. Universidad de Antioquia
187. Universitair Ziekenhuis Leuven
188. Universitat Rovira i Virgili
189. Universitätsspital Basel
190. Université de Tunis El Manar
191. Université Paris Descartes
192. Universiti Sains Malaysia
193. University College London
194. University Health Network, Toronto
195. University Hospital Basel
196. University Hospital of Clermont-Ferrand
197. University of Alabama at Birmingham
198. University of Arizona
199. University of Bonn
200. University of British Columbia
201. University of California
202. University of Campania Luigi Vanvitelli
203. University of Chicago
204. University of Cincinnati
205. University of Eastern Finland
206. University of Greifswald
207. University of Iowa Health Care
208. University of Manchester
209. University of Medicine and Dentistry of New Jersey
210. University of Miami
211. University of Michigan
212. University of New Mexico
213. University of New South Wales
214. University of Oulu
215. University of Rochester
216. University of São Paulo
217. University of Southern California
218. University of Texas
219. University of Toledo Medical Center
220. University of Toronto
221. University of Utah
222. University of Washington Department of Family Medicine
223. University of Wisconsin
224. University of Zurich
225. UPMC Magee-Womens Hospital
226. Usona Institute
227. VA Connecticut Healthcare System 
228. VA Loma Linda Healthcare System 
229. Verrian Ontario 
230. Vyera Pharmaceuticals
231. Washington University
232. West Virginia University
233. Wonkwang University
234. Worldwide Clinical Trials
235. Wuhan General Group
236. Yale University